• The power of local knowledge
    on a global scale.

    No matter where your clinical development takes you, we're already there. Where are you today?

  • We are dedicated to
    the future of clinical development
    and to every life it saves.

    Learn more about why we do what we do, and what we can do for you. Click to read our story.

  • There's just no denying
    good chemistry

    Explore the PRA HEALTH SCIENCES interactive experience to find out what makes us tick.

Social Media

See the latest interactions from our social media


#BioPharmaAsia Industry Awards names #PRAHealthSciences the Best CRO. This is the second time PRA has...

View Post

Featured News

Read the latest updates from our PR department

PRA Health Sciences Expands Global Phase I Patient Strategy

PRA Health Sciences (PRA) is enhancing its global Phase I patient strategy and increasing its clinical footprint with the expansion of its Early Development Services (EDS). These initiatives are...

PRA Health Sciences, Inc. Reports 4th Quarter and Full Year 2014 Results and 2015 Guidance

• $323.8 million of service revenue in the fourth quarter; 8% consolidated service revenue growth compared to the fourth quarter of 2013.

• $50.6 million of Adjusted EBITDA in the...

PRA Health Sciences Announces Appointment of New Director

9 February, 2015, Raleigh, N.C. – PRA Health Sciences, Inc. (NASDAQ: PRAH) today announced the appointment of Matthew P. Young to the Board of Directors of the Company. As a member of the...

Read More >

Media Resources

Explore the latest resources uploaded to our media library

Sign Up for PRA's Industry Watch

Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter

CASE STUDY: PRA Feasibility Leads To Unique Enrollment Strategy

PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.


PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...

CASE STUDY: PRA Teamwork Demonstrates Vision

A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.


Find out what's happening next on PRA's event schedule

April 8 - April 10

The BioKorea Conference aims to provide a platform to discuss and acquire the latest knowledge on various bio topics from diverse areas such as medical care, food, agriculture, energy, chemical and the environment, thereby helping bio professionals exchange expertise and encourage collaboration

April 12 - April 14

The International Society for Pharmacoepidemiology (ISPE) is a non-profit international professional membership organization dedicated to advancing the health of the public by providing a forum for the open exchange of scientific information and for the development of policy; education; and advocacy for the field of pharmacoepidemiology, including pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness […]

April 13 - April 17

The Canadian Forum for Analytical and Bioanalytical Sciences (CFABS) is a Non-Profit Scientific Organization Formed to Promote Exchange of Knowledge and Sharing of Ideas in Analytical and Bioanalytical Sciences. The analytical & bioanalytical sciences and specifically mass spectrometry, chromatography, immunochemistry and related techniques have expanded beyond imagination in the last few years with new technologies […]

Read More >